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of dilated cardiomyopathy (9 [23.1%]), or mixed 
(functional and degenerative; 4 [10.3%]). Pulmo‑
nary hypertension was present in 17 patients 
(43.6%), chronic atrial fibrillation in 12 (30.8%), 
and chronic obstructive pulmonary disease 
(COPD) in 7 (17.9%).
In all patients, mitral valve repair involved 
restrictive mitral ring annuloplasty and was 
performed via median sternotomy. In 6 cases, 
an additional mitral valve repair procedure, se‑
lected based on the mechanism of MR, was per‑
formed. Twenty seven patients (69.2%) under‑
went a concomitant intervention: coronary ar‑
tery bypass grafting (19 [48.7%]), tricuspid an‑
nuloplasty (11 [28.2%]), and radiofrequency ab‑
lation for atrial arrhythmia (3 [7.7%]); 3 of them 
underwent 2 additional procedures.
Follow ‑up Having obtained local ethics com‑
mittee approval, we accessed data on survival 
and dates of death of all patients from the Pol‑
ish Ministry of the Interior and Administration. 
Thirty four demographic, clinical, and echocar‑
diographic parameters were analyzed to identify 
the independent risk factors for late mortality.
Statistical analysis All statistical analyses were 
performed using the Statistica 6.0 software 
(StatSoft, Poland). Continuous variables were 
compared with the t test or the Mann–Whitney 
test, and categorical variables with the χ2 test. 
First, we used univariate Cox analysis to iden‑
tify variables predicting mortality, and then 
the significant variables were included in mul‑
tivariable Cox regression to determine the inde‑
pendent risk factors for mortality. Late survival 
Introduction Heart failure often coexists with 
mitral regurgitation (MR), which could be diag‑
nosed in up to 60% of patients with left ventricu‑
lar ejection fraction (LVEF) lower than 40%. Sig‑
nificant (moderate or severe) MR occurs in 1 in 
6 patients in this population.1 Moreover, it was 
shown that MR impairs long ‑term prognosis in 
patients with heart failure (HF).1 As MR is the re‑
sult of geometric and functional abnormalities 
of the left ventricle rather than their cause in 
both ischemic and dilated cardiomyopathy, it is 
still controversial whether the long ‑term effect 
of mitral valve repair recompenses the high op‑
erative risk in this group of patients. The aim of 
this study was to assess the early and long ‑term 
outcomes in patients with decreased LVEF who 
underwent mitral valve repair and to determine 
the predictors of long ‑term survival.
Methods We retrospectively analyzed 
the medical records of 39 patients (mean [SD] 
age, 63 [12] years) who underwent mitral valve 
repair due to significant MR and who were pre‑
operatively diagnosed with impaired left ventric‑
ular function defined as LVEF ≤40% (mean [SD] 
LVEF, 32.3% [5.7%]; range, 15%–40%). The pa‑
tients scheduled for concomitant aortic valve 
surgery, surgical ventricular restoration, or 
surgery due to infective endocarditis were ex‑
cluded from the study. The majority of patients 
(31 [79.5%]) had significant symptoms, with New 
York Heart Association class 3 or 4 assigned, al‑
though only 1 patient required inotropic support 
and an intra ‑aortic balloon pump before surgery. 
The etiology of mitral valve insufficiency was 
ischemic (26 [66.7%]), functional in the course 
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on the first postoperative day, but almost one 
third of the study population (12 [30.8%]) was 
inotrope ‑dependent for over 2 days. We also 
used an intra ‑aortic balloon pump (in 6 patients 
[15.4%]) relatively often compared with the re‑
sults presented by other authors (2.4%3 and 
8.2%4). However, it did not correlate with in‑
creased mortality (as discussed below) or an in‑
creased rate of renal failure, which is a sensitive 
indicator of hemodynamic compromise. Com‑
pared with other studies, the number of patients 
requiring temporary renal replacement thera‑
py (1 [2.6%]) was similar4 or even lower.3 It may 
suggest that the aggressive treatment of hemo‑
dynamic instability gives an opportunity to sta‑
bilize the patient and avoid organ failure. Al‑
though the need for intense postoperative ino‑
tropic support (at least 2 inotropes for at least 
48 hours) did not increase early mortality, it was 
a strong predictor of worse long ‑term prognosis. 
However, survival probability started to differ 
significantly between patients who required in‑
tense inotropic support and those who did not 
after 1‑year follow ‑up (FIGURE 1). In our opinion, 
exacerbated postoperative HF is just a mark‑
er of a more advanced disease and limited com‑
pensatory reserve.
In our study, only 1 patient died in the ear‑
ly postoperative period. Thirty ‑day mortality 
was 2.6%, which is lower than 3.25% predicted 
by the EuroSCORE II risk model. As previously 
shown, early mortality depends on procedure 
complexity, starting from 0.5% in isolated mi‑
tral valve repair5 and raising up to 6.1%6 when 
a concomitant surgery is performed.
In our study, the median (interquartile range) 
follow ‑up of hospital survivors was 41 (26–61) 
months. Twelve deaths occurred after a median 
(interquartile range) time of 19 (13–32) months, 
which accounts for the overall cumulative sur‑
vival of 57% in the study group. The 2‑ and 5‑year 
cumulative survival rates were 77% and 66%, 
respectively.
As for the last 15 years we have observed a rev‑
olution in the transcatheter treatment of MR, 
there needs to be a place for discussion about 
the surgical outcomes in the context of percuta‑
neous intervention. The introduction of the Mi‑
traClip system has provided new perspectives 
for patients at  high surgical risk. However, 
the 2‑year mortality rate of about 30% is expect‑
able in patients with HF undergoing transcathe‑
ter mitral valve repair, which was confirmed by 
Rosa et al7 in their meta ‑analysis of 23 studies on 
the MitraClip implantation. Against this back‑
ground, the 2‑year mortality of 23% observed in 
our study group can be treated as an acceptable 
and explicable risk, especially if almost 70% of 
the patients underwent a complex cardiac sur‑
gery. Data on a longer follow ‑up in the popula‑
tion with HF after transcatheter mitral valve re‑
pair are currently insufficient. On the contrary, 
was analyzed with the Kaplan–Meier method. 
The probability of survival in 2 study groups was 
compared with the log ‑rank test. A P value less 
than 0.05 was considered significant.
Results and discussion Regarding preop‑
erative clinical parameters, only COPD was 
proven to be a risk factor for all ‑cause mortal‑
ity in our study (HR, 7.95; 95% CI, 6.66–9.25; 
P = 0.002). This disease is similar to HF in many 
respects—it is a progressive disease, usually 
with poor prognosis. Therefore, it is not sur‑
prising that the coexistence of COPD and HF af‑
fects patients’ survival.2 Pulmonary hyperten‑
sion could potentially link COPD with increased 
mortality in patients with HF. However, in our 
study, the presence of echocardiographic signs 
of pulmonary hypertension did not influence 
patients’ prognosis.
The second predictor of worse survival was 
the need to receive extensive postoperative 
inotropic support (HR, 7.76; 95% CI, 6.52–9; 
P = 0.001). Inotropes are an obvious choice to 
prevent and treat postoperative complications 
related to hemodynamic instability in patients 
with preoperative HF. In our center, anesthesi‑
ologists routinely start administering inotropes 
at the time of weaning the patient from cardio‑
pulmonary bypass and continue the treatment 
for a few hours after surgery, adjusting the dose 
and type of catecholamines to the patient’s con‑
dition. In the present study, the majority of pa‑
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FIGURE1 Long ‑term cumulative survival depending on postoperative inotropic support




















the long ‑term effects of surgical mitral valve 
repair were described in numerous reports yet 
in small populations.6,8-10 The estimated 5‑year 
survival rate ranged from about 55% to 80%,6,8-10 
with a mean value close to our outcome (66%). 
As highlighted by many authors, poor progno‑
sis in patients with HF and MR, independently 
of an intervention performed, is in fact the con‑
sequence of cardiomyopathy, which is the ma‑
jor contributor to disease progression. A similar 
conclusion was presented by Jin et al11 in a study 
on the impact of MR on the outcomes of cardi‑
ac resynchronization therapy (CRT)—anoth‑
er procedure which can reduce MR: although 
a decrease of at least 1 MR level was observed 
in about 70% of patients with significant MR 
6 months after receiving CRT, significant MR be‑
fore implantation remained a predictor of worse 
clinical outcomes, mainly of an increased rate of 
HF ‑related hospitalizations. Whether a patient 
with an indication for CRT should be referred 
for mitral valve repair is an important issue, 
however beyond the scope of the current report. 
Shortly, we believe that the decision should be 
made on a case ‑by ‑case basis and by a multidis‑
ciplinary team including a electrophysiologist.
To conclude, in high ‑volume centers with 
experienced teams of cardiac surgeons and 
anesthesiologists, surgical mitral valve repair 
may be an efficient and safe strategy for select‑
ed patients with coexistent MR and left ven‑
tricular dysfunction, even in the era of trans‑
catheter interventions. The possibility to de‑
liver comprehensive treatment, eg, simulta‑
neous coronary revascularization or tricuspid 
valve repair, is an advantage of an open ‑heart 
surgery. Nevertheless, long ‑term outcomes are 
still unsatisfactory, being severely diminished 
by the progressive nature of HF and comorbid‑
ities like COPD.
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